Eli Lilly | LLY - Sales Revenues


Eli Lilly reported $19.8B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Abbott USD 12.59B 1.43B Jun/2026
ALKERMES USD 392.91M 8.41M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
Baxter International USD 2.7B 270M Mar/2026
Biogen USD 2.25B 30M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Drreddys Laboratories INR 789.05M 86.48B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
J&J USD 25.31B 1.21B Jun/2026
Medtronic USD 9.8B 800M Mar/2026
Merck USD 16.29B 110M Mar/2026
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Novartis USD 14.41B 1.3B Jun/2026
Novartis USD 13.11B 750M Mar/2026
Novo Nordisk DKK 96.82B 17.68B Mar/2026
Perrigo USD 969M 141M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Prestige Brands USD 281.62M 1.82M Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 11.24B 60M Mar/2026
Sanofi EUR 12.14B 65M Mar/2026
United Therapeutics USD 781.5M 8.7M Mar/2026
Zoetis USD 2.3B 100M Mar/2026